reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a
May 03, 2022 02:00 ET
|
reMYND
PRESS RELEASE reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage...
Alzheimer’s Patient Advocates File FOIA Seeking Answers on Discriminatory Medicare Coverage Decision
April 15, 2022 11:42 ET
|
UsAgainstAlzheimer's
Washington, D.C., April 15, 2022 (GLOBE NEWSWIRE) -- Today, UsAgainstAlzheimer’s announced their latest effort to demand answers from the Centers for Medicare and Medicare Services (CMS) about last...
Neurological Biomarkers Market by Application, by Type, by End-use, by Region and Forecasts to 2028
December 06, 2021 06:58 ET
|
Research and Markets
Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's), By Type (Genomic, Proteomic), By...
Actipulse Neuroscience Announces Successful Clinical Trial Using Fast Gamma Magnetic Stimulation for the Treatment of Alzheimer's Disease
September 30, 2021 15:00 ET
|
Actipulse Neuroscience
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Today, the results of a recent pilot clinical trial, funded by neurotech company Actipulse Neuroscience, have demonstrated that its non-invasive...
Outlook on the Neurological Diseases Treatment Global Market to 2029 - Key Drivers, Challenges and Opportunities
April 29, 2021 07:18 ET
|
Research and Markets
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Neurological Diseases Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...
Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24
March 19, 2021 07:45 ET
|
Longeveron Inc.
MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for...
LSU Professor Gartia Receives NSF CAREER Award for Alzheimer’s Research
March 03, 2021 12:20 ET
|
LSU College of Engineering
BATON ROUGE, La., March 03, 2021 (GLOBE NEWSWIRE) -- LSU Mechanical Engineering Professor Manas Gartia was recently given a National Science Foundation CAREER Award for his project, “Multimodal...
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
February 24, 2021 16:05 ET
|
Prothena Corporation plc
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s diseaseNew pre-specified exploratory subgroup analyses and new digital...
Insights on the Genetic Testing for Epilepsy, Autism, Alzheimer's and Other Neurologic Conditions Global Market to 2025
February 15, 2021 05:43 ET
|
Research and Markets
Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Genetic Testing Markets for Epilepsy, Autism, Alzheimer's and Other Neurologic Conditions" report has been added to ResearchAndMarkets.com's offering. ...
Avenir Senior Living Inc. Launches on DealSquare
December 07, 2020 14:38 ET
|
DealSquare Technologies Inc.
TORONTO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avenir Senior Living Inc. (“Avenir”), a full-service developer, owner, and operator of luxurious private-pay memory care communities and seniors...